Discounted Cash Flow
Agilon Health, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2020 | $1.2b | $-60.1m | $-55.0m | -4.9% | — |
| 2021 | $1.8b (50.5%) | $-406.5m (-576.9%) | $-154.7m (-181.4%) | -22.2% (-349.8%) | — |
| 2022 | $2.7b (47.7%) | $-106.6m (73.8%) | $-146.2m (5.5%) | -3.9% (82.3%) | — |
| 2023 | $4.3b (59.4%) | $-262.6m (-146.4%) | $-172.0m (-17.6%) | -6.1% (-54.6%) | — |
| 2024 | $6.1b (40.4%) | $-260.2m (0.9%) | $-71.0m (58.7%) | -4.3% (29.4%) | — |
| 2025 | $5.9b (-2.1%) | $-391.3m (-50.4%) | $-119.0m (-67.5%) | -6.6% (-53.7%) | — |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.